CTRI/2022/11/047055尚未招募3 期
A Multicentric, Randomized, Double Blind, Double Dummy, Parallel Group, Comparative, Phase-III Clinical Study to Evaluate the Efficacy, Safety and Tolerability of FDC of Metoprolol succinate 50 mg plus Amlodipine 5 mg plus Telmisartan 40 mg tablets, versus Co administration of Metoprolol succinate 50 mg and Telmisartan 80 mg tablets in subjects with Uncontrolled Essential Hypertension with stable Coronary Artery Disease (CAD).
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female subjects aged between 18 and 75 years.
- •2.Subjects of stable coronary artery disease.
- •3.Subjects with the history of uncontrolled essential hypertension with stable coronary artery disease [having seated diastolic BP (SeDBP) 90 to 110 mmHg and seated systolic BP (SeSBP) 140 to 180 mmHg] who is on the stable dose of Metoprolol succinate ER 50 mg plus Telmisartan 40 mg Tablets for at least 4 weeks.
- •4.Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.
- •5.Female subjects of childbearing potential must be willing to use acceptable method of contraception or post-menopausal for at least one year or surgically sterile.
排除标准
- •1.Suspected hypersensitivity to either of the study medications or any of the ingredients of the formulation.
- •2.Subjects with EF less than 40% as per Simpsonâ??s method on 2D Echo.
- •3.Subjects diagnosed with Secondary or Malignant Hypertension.
- •4.Surgical or medical condition that, in the judgment of the Investigator, could interfere with absorption, distribution, metabolism, or excretion of the drugs to be used.
- •5.Renal system:
- •Subjects with eGFR more than 60 mL per min per 1.73m2
- •Subjects with abnormal lab values of Na, K, Mg and Uric acid. normal range: Na
- •Equal to135 to 145 mEq per L, K equal to 3.5 to 5.0 mmol per L, Mg equal to 7 to 12 mg per dL and Uric acid 3.5 to 7.2 mg per dL
- •6.Hepatic system:
- •Subjects with abnormal Liver Function Test with values more than 2.5 times the upper limit of normal.
- •7.Endocrine system:
- •Subjects with abnormal Thyroid Function Test, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus with HbA1c value greater than 8%.
- •8.Cardiovascular system:
- •Subjects with known case of symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) less than one year or coronary artery bypass graft (CABG) surgery less than one year, sinus node dysfunction and any clinically significant cardiac arrhythmias.
- •Subjects with known case of Stroke.
- •9.Other disease conditions
- •Subject with clinical history of COPD, Bronchial Asthma and Peripheral Vascular disease.
研究者
相似试验
招募中
3 期
Diabetic Peripheral Pain Coexisting with Vitamin B12 deficiency to treat with FDC of Pregabalin plus Methylcobalamin plus Duloxetine (Delayed Release) Capsules.CTRI/2024/01/062147Ravenbhel Healthcare Pvt. Ltd.
尚未招募
3 期
A clinical study to assess the efficacy and safety of Pregabalin, Duloxetine and Mecobalamin Capsules in neuropathic pain patients.CTRI/2024/03/063691Synokem Pharmaceuticals Ltd
尚未招募
3 期
A clinical study to see the effect and safety of Fixed Dose Combination of Silodosin and Solifenacin Capsules in Comparison to Silodosin Capsules in Male Patients Having Benign Prostatic Hyperplasia (BPH)/ Lower Urinary Tract Symptoms (LUTS) with Over Active Bladder (OAB)CTRI/2020/07/026419Sun Pharma Laboratories Limited
已完成
3 期
A clinical study to assess the efficacy and safety of combination of Azilsartan and Amlodipine Tablets in patients with hypertension.CTRI/2022/02/040081Inventia Healthcare Ltd309
已完成
3 期
A clinical study to assess the efficacy and safety of Imeglimin Tablets in patients with diabetes.CTRI/2022/02/040348Exemed Pharmaceuticals216